Whole Exome Sequencing in Coronary Artery Ectasia

Completed

• Conditions: Coronary Aneurysm; Coronary Ectasia
• Interventions: Diagnostic Test: Whole exome sequencing

• Registration Number: NCT06001957
• Lead Sponsor: Jagiellonian University

Brief Summary

The goal of this observational study is to assess the role of the whole exome sequencing (WES) application in patients with giant coronary artery ectasia (CAE) with a high-risk of genetic background.

The main question it aims to answer are:

* the assessment of role of WES in CAE

* the detection of novel pathogenic mutations associated with CAE development

Detailed Description

Coronary artery aneurysm and ectasia (CAAE) is defined as a dilation of the coronary artery by at least 1.5 times compared to the adjacent segment. The incidence of CAAE is reported in 0.3-5.3% of patients undergoing coronary angiography. Giant CAAE is a rare phenomenon characterized by a dilation of a coronary artery exceeding 2 to 4 centimeters and it was found only in 0.02% of patients undergoing coronary angiography.

The most common etiology of CAAE is atherosclerosis, followed by Kawasaki disease, infectious septic emboli, connective tissue disease and arteritis. Iatrogenic causes are less common.

There are few genetic reports on potential loci associated with CAAE. Meta-analysis of genome wide association studies performed in European and Japanese population of children with Kawasaki disease has identified ITPKC, FCGR2A, CASP3 and FAM167A genomic regions to be associated with susceptibility to develop CAAE. Furthermore, 9p21 variant has been linked with coexistence of coronary artery disease, cerebral artery aneurysms and aortic aneurysms, mainly due to suspected potential adverse vascular remodeling. Nevertheless, the direct association of specific genetic variants with CAAE formation, especially with those giants, has not been proven.

Therefore, the investigators aim to assess the role of the whole exome sequencing (WES) application in patients with giant coronary artery ectasia (CAE) with a high-risk of genetic background.

Study Timeline

• Study Start: 2022-03-23
• Primary Completion: 2023-06-11
• Status Verified: 2023-08
• Study Completion: 2023-08-15
• Study First Submitted: 2023-08-15
• Study First Submitted QC: 2023-08-18
• Last Update Submitted: 2023-08-18
• Study First Posted: 2023-08-21
• Last Update Posted: 2023-08-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1

Inclusion Criteria

• diagnosed giant coronary artery aneurysm and ectasia (CAAE)
• high risk of genetic background

Exclusion Criteria

• the lack of informed consent for whole exome sequencing (WES) analysis

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Proband	Whole exome sequencing	Patient with extremely giant coronary artery ectasia (CAE) and positive family history

Primary Outcome Measures

Name	Time	Method
The novel pathogenic mutations associated with CAE development	Until June 11, 2023	Reads of WES will be aligned to the hg38 reference genome sequence and visualized by Integrative Genomic Viewer.

Trial Locations

Locations (1)

Department of Coronary Disease and Heart Failure, John Paul II Hospital in Krakow, Jagiellonian University Medical College; 🇵🇱 Kraków, Poland